Restoring invisible and abandoned trials – new podcast episode

Communications / 01 October 2020

Photo by Pau Casals on Unsplash

In the new episode of the Drug Safety Matters podcast, explore the problem of the data we don't see and find out what can be done to peel back the curtain.


Clinical trials are the “gold standard” of evidence-based medicine – the best way we have to test whether a drug is safe and effective before it enters the market. But if trial data is poorly reported or – even worse – left unpublished, how are we supposed to determine the true value of a medical treatment?

Peter Doshi, associate editor at The BMJ and founder of the Restoring Invisible and Abandoned Trials (RIAT) Support Center, has made it his mission to fix the problem and improve data transparency for good.

Subscribe by visiting the Drug Safety Matters website or listen in right here:

Learn more

To find out a lot more about Peter Doshi and his work, be sure to visit the RIAT Support Center here.

Peter Doshi on Drug Safety Matters. Photo: UMC

Related Articles

Winning the war against health mis and disinformation

Ronald Meyboom: A professional life devoted to pharmacovigilance

Pharmacovigilance: Back to the Future with ISoP 2025

You may also like

Winning the war against health mis and disinformation

Public health is at risk now more than ever; with AI it has never been easier to spread mis- and disinformation on health. How do we work smarter to address this threat?

17 June 2025

Ronald Meyboom: A professional life devoted to pharmacovigilance

Ronald Meyboom, pioneering pharmacovigilance expert who helped establish drug safety monitoring in the Netherlands, died 27 April. He was 79.

11 June 2025

Pharmacovigilance: Back to the Future with ISoP 2025

The theme of this year’s conference is inspired by Cairo’s rich cultural and scientific history and commitment to advancing drug safety and regulatory science.

19 March 2025